

A.P. Pharma

[View the current A.P. Pharma Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/21-A.P.++Pharma.html)

(<http://www.bioportfolio.com/biocorporate/21-A.P.++Pharma.html>)

Contact Details:

123 Saginaw Drive

Redwood City

CA

94062

United States of America

Tel: 650-366-2626

Fax:

Email: busdev@appharma.com

A.P. Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative medical treatments utilizing its proprietary polymer-based drug delivery systems.

The Company's primary emphasis is on advancing its Biochronomer™ technology platform for site-specific and systemic drug delivery. Designed to release drugs over a period of hours, days, weeks or even months, Biochronomer systems can be fabricated into a wide range of solid and free-flowing gel forms which erode away as they deliver the drug. A variety of injectable and implantable applications are undergoing feasibility testing to address major unmet needs in pain management, inflammation, oncology, ophthalmology and other medical fields.

The Company's current product development programs are funded by royalties from topical prescription products marketed by pharmaceutical partners and proceeds from the divestiture of its cosmeceutical product lines.

Recent Publications by A.P. Pharma:



- [Post surgical pain management with poly\(ortho esters\).](#)

Poly(ortho esters), POE, are synthetic bioerodible polymers that can be... 22nd April, 2003

A.P. Pharma, 123 Saginaw Drive, Redwood City, CA 94063, USA.- Adv Drug Deliv Rev. 2002 Oct 16;54(7):1041-8.

- [Poly\(ortho esters\): synthesis, characterization, properties and uses.](#)

Over the last 30 years, poly(ortho esters) have evolved through four... 22nd April, 2003

A.P. Pharma, 123 Saginaw Drive, Redwood City, CA 94063, USA.- Adv Drug Deliv Rev. 2002 Oct 16;54(7):1015-39.

- [Anika Therapeutics Announces Exclusive Canadian Distribution Agreement for ELEVESS\(R\) with Canderm Pharma Inc](#)
SmartBrief: Oct 5 2008 5:39AM Matching: pharma
- [3 Pharma ETFs for a Sickly Market](#)
Seeking Alpha: Oct 5 2008 10:34AM Matching: pharma
- [A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV](#)
Pharma Live: Oct 4 2008 1:01AM Matching: pharma
- [A P Pharma announces positive phase 3 results of APF530](#)
PharmaBiz: Oct 4 2008 8:53AM Matching: pharma
- [York Pharma Plc Announces The Acquisition Of Leading Dermatological & Wound Care Brands DiGiTAL50](#)
Oct 4 2008 6:28AM Matching: pharma
- [Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileu](#)
Pharma Live: Oct 4 2008 1:02AM Matching: pharma
- [Sun Pharmaceutical Extends Tender Offer for Taro](#)
AndhraNews.net: Oct 4 2008 9:39AM Matching: pharma
- [Disclosure in accordance with the Transparency Legislation of May 2, 2007](#)
Pharma Live: Oct 4 2008 8:45PM Matching: pharma
- [Bayer s Novel Anticoagulant Xarelto Now Also Approved in the EU](#)
Pharma Live: Oct 4 2008 12:35AM Matching: pharma
- [BioAlliance Pharma SA : BioAlliance Pharma employees to participate in the Odyssey breast cancer cha](#)
PR-USA.net: Oct 3 2008 11:34AM Matching: pharma
- [York Pharma Plc Announces The Acquisition Of Leading Dermatological & Wound Care Brands](#)
TradingMarkets: Oct 3 2008 6:16PM Matching: pharma
- [York Pharma Plc Announces The Acquisition Of Leading Dermatological & Wound Care Brands](#)
Calibre Macro World: Oct 3 2008 6:04PM Matching: pharma
- [York Pharma lights the path for British biotech with 'transformative' 22.5m deal](#)
Business Weekly UK: Oct 3 2008 4:20PM Matching: pharma
- [Bioniche Pharma Receives FDA Approval for 10 mg/mL Strength of Ketamine Hydrochloride Injection, USP](#)
Pharma Live: Oct 3 2008 8:50PM Matching: pharma
- [Bayer starts new research cooperation in Asia](#)
Pharma Live: Oct 3 2008 7:58PM Matching: pharma

A.P. Pharma Patents:



- 7220414- [Degradable polyacetal polymers](#)
- 7163694- [Bioerodible poly\(ortho esters\) from dioxane-based di\(ketene acetals\), and block copolymers](#)

[containing them](#)

- 7045589- [Bioerodible poly\(ortho esters\) from dioxane-based di\(ketene acetals\), and block copolymers containing them](#)
- 6946145- [Block copolymers based on poly\(ortho esters\) containing amine groups](#)
- 6863782- [Method of preparing di\(ketene acetals\)](#)
- 6861068- [Pharmaceutical compositions using semi-solid delivery vehicle](#)
- 6667371- [Block copolymers based on poly\(ortho esters\) containing amine groups](#)
- 6613355- [Semi-solid delivery vehicle and pharmaceutical compositions](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

